Ren Chuanli, Chen Hui, Han Chongxu, Fu Deyuan, Wang Fuan, Wang Daxin, Ma Li, Zhou Lin, Han Dongsheng
Clinical Medical Testing Laboratory, Northern Jiangsu People's Hospital and Clinical Medical College of Yangzhou University, Yangzhou, China.
Department of Epidemiology and Biostatistics, Ministry of Education (MOE) Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China.
Oncotarget. 2016 Jun 14;7(24):36655-36665. doi: 10.18632/oncotarget.9131.
Fibroblast growth factor (FGF) 9 is a member of the FGF family, which promotes carcinogenesis in some solid tumours. However, its biological and prognostic significance in gastric cancer (GC) is unclear. We examined FGF9 expression in 180 GC and corresponding non-tumorous gastric tissue samples by immunohistochemistry and evaluated its role in predicting tumour prognosis. Knockdown of FGF9 by siRNA inhibited cell growth and induced apoptosis in GC cell lines. Fifty of the 180 GC specimens (27.8%) had high FGF9 protein expression, whereas decreased or unchanged expression was observed in 130 cases (72.2%). High FGF9 expression was a significant predictor of poor survival (28.1 vs. 55.8 months, P < 0.001). After stratification according to AJCC stage, FGF9 remained a significant predictor of shorter survival in stage II (30.6 vs. 64.9 months, P < 0.001) and stage III GC (29.7 vs. 58.9 months, P < 0.001). Multivariate and univariate analysis showed that higher expression of FGF9 can be used as a predictor for poor prognosis (HR, 2.95; 95% CI, 1.97-4.41; P < 0.001; and HR, 2.94; 95% CI, 2.01-4.31; P < 0.001, respectively). FGF9 may provide the anti-apoptotic function and be useful as a novel independent marker for evaluating GC prognosis.
成纤维细胞生长因子（FGF）9是FGF家族的一员，在某些实体瘤中可促进肿瘤发生。然而，其在胃癌（GC）中的生物学及预后意义尚不清楚。我们通过免疫组织化学检测了180例GC及相应非肿瘤性胃组织样本中FGF9的表达，并评估其在预测肿瘤预后中的作用。通过小干扰RNA（siRNA）敲低FGF9可抑制GC细胞系的细胞生长并诱导其凋亡。180例GC标本中有50例（27.8%）FGF9蛋白表达高，而130例（72.2%）表达降低或无变化。FGF9高表达是生存不良的显著预测指标（28.1个月对55.8个月，P<0.001）。根据美国癌症联合委员会（AJCC）分期进行分层后，FGF9仍然是Ⅱ期（30.6个月对64.9个月，P<0.001）和Ⅲ期GC（29.7个月对58.9个月，P<0.001）患者生存时间较短的显著预测指标。多因素和单因素分析均显示，FGF9高表达可作为预后不良的预测指标（风险比分别为2.95；95%置信区间为1.97 - 4.41；P<0.001；以及风险比为2.94；95%置信区间为2.01 - 4.31；P<0.001）。FGF9可能具有抗凋亡功能，可作为评估GC预后的新型独立标志物。
